Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05956158

RISE: A Remote Study of Insomnia Treatment in Crohn's Disease

The purpose of this study is to assess whether the investigators can treat insomnia in people with Crohn's disease, and if insomnia treatment can make other things better, like pain or inflammation.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Insomnia Crohn Disease Digestive System Diseases Dyssomnias Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases Mental Disorders Nervous System Diseases Sleep Disorders, Intrinsic Sleep Initiation and Maintenance Disorders Sleep Wake Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States

About this study

People with Crohn's disease often suffer from sleep problems. Long term, sleep problems may lead to more flares of Crohn's disease or other complications. In general, patients with Crohn's disease also report that sleep problems can worsen symptoms of Crohn's disease the next day. In people with other medical problems, research has also shown that having sleep problems can make other things worse, such as pain and inflammation. In this study, the investigators want to understand if they can treat sleep problems in people with Crohn's disease, and what else might improve if sleep gets better. If this study is successful, it will help the investigators understand more about how to treat insomnia in people with Crohn's disease and how sleep impacts pain and inflammation. Long term, this information will be helpful in understanding how best to take care of people with Crohn's disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mild to moderate CD based on PRO-3 & 50% with objective evidence of active disease
  • Insomnia Severity Index score ≥ 8 and SOL or WASO ≥ 30 minutes
  • Stability of sleep & CD meds for ≥ 3 months
  • Access to internet or cell phone service sufficient for telehealth

Exclusion criteria

  • PHQ-9 depression score ≥ 15
  • GAD-7 anxiety score ≥ 15
  • Unstable major psychiatric condition (e.g., bipolar disorder, psychotic disorder)
  • Current alcohol or substance abuse
  • Current opioid use for pain control
  • Current systemic corticosteroid use
  • Current pregnancy or nursing
  • Ileostomy or colostomy
  • Diagnosis of seizure disorder
  • Diagnosis of sleep apnea or positive WatchPAT screen
  • Diagnosis of restless leg syndrome or positive Cambridge-Hopkins RSLq screen
  • Night shift, rotating shift work, or frequent travel outside of time zone

Treatment and study plan

Behavioral Treatment

Behavioral

This treatment is designed to help participants make changes to behavior patterns and thoughts that contribute to insomnia.

Other names: Cognitive Behavioral Therapy for Insomnia, CBT-I

Sleep Education Treatment

Behavioral

This treatment is designed to help participants understand the relationships among sleep, pain, and Crohn's disease and to make changes to insomnia-related behaviors.

Primary outcomes

  1. Feasibility of the intervention as measured by attrition rate over time

    Time frame: Baseline, 8 weeks, 21 weeks, and 34 weeks

    Attrition rate will be based on the percentage of participants who have dropped out of the trial at different time points.

  2. Feasibility of the intervention as measured by recruitment rate over time

    Time frame: From study initiation until we are no longer actively recruiting (approximately 24 months)

    Recruitment rate will be based on the number of participants who are recruited into the trial per month.

  3. Feasibility of the intervention as measured by assessment completion at multiple time points

    Time frame: Baseline, 8 weeks, 21 weeks, and 34 weeks

    Assessment completion rate will be based on the percentage of participants who complete all the required questionnaires and tasks at each time point.

  4. Feasibility of the intervention as measured by qualitative interviews

    Time frame: 8 weeks and 34 weeks

    Feasibility will be based on interview-derived themes related to barriers and facilitators to study engagement. Data will be collected at two time points to ensure completeness of themes.

  5. Acceptability of the intervention as measured by visit completion

    Time frame: 8 weeks

    Visit completion will be based the number of visits (out of 5) completed by each participant.

  6. Treatment acceptability questionnaire score

    Time frame: 1 week

    The Treatment Acceptability Questionnaire is a 4-item self-report questionnaire designed to assess the overall acceptability of an intervention. Scores range from 1 to 4 and higher scores are indicative of greater acceptability.

  7. Acceptability of the intervention as measured by qualitative interviews

    Time frame: 8 weeks

    Acceptability will be based on interview-derived themes related to aspects of the intervention that participants found helpful and unhelpful.

Secondary outcomes

  1. Change in insomnia symptoms as measured by the Insomnia Severity Index

    Time frame: Baseline, 8 weeks, 21 weeks, and 34 weeks

    The Insomnia Severity Index (ISI) is a self-report questionnaire designed to measure severity of insomnia. The ISI is made up of 7 items on insomnia symptoms and related impairments and total scores range from 0-28. Higher scores are indicative of greater insomnia symptoms.

  2. Change in diary-based sleep onset latency

    Time frame: Baseline, 8 weeks, 21 weeks, and 34 weeks

    A weekly average of self-reported time it takes to fall asleep each night, derived from a self-reported sleep diary

  3. Change in diary-based wake after sleep onset

    Time frame: Baseline, 8 weeks, 21 weeks, and 34 weeks

    A weekly average of self-reported time spent awake in the middle of each night, derived from a self-reported sleep diary

  4. Change in Crohn's disease symptoms as measured by the Patient Reported Outcomes 3

    Time frame: Baseline, 8 weeks, 21 weeks, and 34 weeks

    The Patient Reported Outcomes 3 (PRO-3) is a self-report questionnaire designed to measure the severity of Crohn's disease symptoms in the past week. The PRO-3 is made up of 3 items (stool frequency, pain, and well-being) and higher scores are indicative of more severe symptoms. Scores are interpreted as follows: <13=quiescent or inactive disease; 13-21=mildly active disease; 22-52=moderately active disease; 53 and up=severely active disease.

Other outcomes

  1. Change in C-reactive protein

    Time frame: Baseline, 8 weeks, and 21 weeks

    We will measure blood levels of C-reactive protein

  2. Change in fecal calprotectin

    Time frame: Baseline, 8 weeks, and 21 weeks

    We will measure levels of fecal calprotectin via a stool sample.

  3. Change in sleep architecture

    Time frame: Baseline, 8 weeks, and 21 weeks

    We will measure changes in percent time spent in light sleep, deep sleep, and rapid eye movement (REM) sleep using the Oura ring.

  4. Change in behaviorally assessed pain tolerance via the Cold Pressor Test

    Time frame: Baseline, 8 weeks, and 21 weeks

    The Cold Pressor Test involves submerging one's non-dominant hand in ice water and rating discomfort at regular, pre-determined intervals. Pain tolerance will be measured based on the total amount of time a participant can keep their hand submerged, with a maximum of 3 minutes.

  5. Change in diary-based sleep efficiency

    Time frame: Baseline, 8 weeks, 21 weeks, and 34 weeks

    Change in sleep efficiency (total sleep time / time in bed), derived from a self-reported sleep diary.

  6. Change in objective sleep onset latency

    Time frame: Baseline, 8 weeks, and 21 weeks

    Change in the time it takes to fall asleep each night, derived from the Oura ring.

  7. Change in objective wake after sleep onset

    Time frame: Baseline, 8 weeks, and 21 weeks

    Change in the time spent awake in the middle of the night, derived from the Oura ring.

  8. Change in objective sleep efficiency

    Time frame: Baseline, 8 weeks, and 21 weeks

    Change in sleep efficiency (total sleep time / time in bed), derived from the Oura ring.

Sponsors and collaborators

Lead sponsor

Dartmouth-Hitchcock Medical Center

Other

Registry information

Acronym: RISE

Important dates

Study start
2023
Primary completion
2026
Study completion
2027
First posted
Jul 21, 2023
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.